DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Rosuvastatin
Drug: CKD-508 Tablet

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT06979973

Locations: 🇺🇸
Research Site, Glendale, California, United States

Retrospective Observational Study on GERD Management in General Hospitals in Korea

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 13750

Registration Number: NCT06974903

Locations: 🇰🇷
Hanyang University Hospital, Seoul, Seongdong-gu, Korea, Republic of

Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981

Phase 2

Recruiting

Conditions: Knee Osteoarthritis

Interventions: Device: CKD-981(1)
Device: CKD-981(2)
Device: Sham device
Drug: Placebo Drug
Drug: Reference Drug

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 100

Registration Number: NCT06954766

Locations: 🇰🇷
Wonju Severance Christian Hospital, Wonju, Korea, Republic of

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Phase 4

Not yet recruiting

Conditions: Heart Transplant

Interventions: Drug: Everolimus
Drug: Mycophenolate mofetil Tablet/Capsule

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 140

Registration Number: NCT06942156

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Phase 3

Not yet recruiting

Conditions: Androgenetic Alopecia

Interventions: Drug: CKD-843 dose#1
Drug: CKD-843 dose#2
Drug: Placebo of CKD-843 dose
Drug: Placebo of Dutasteride Capsule
Drug: Dutasteride Capsules

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 288

Registration Number: NCT06916793

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: SGLT2 inhibitor
Drug: Thiazolidinedione
Drug: DPP-4 inhibitor

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 10000

Registration Number: NCT06838286

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: D352
Drug: D794

First Posted Date: 2025-01-06

Last Posted Date: 2025-05-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT06758661

Locations: 🇰🇷
H Plus Yangji Hospital, Gwanak-gu, Seoul, Korea, Republic of

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Subjects

Interventions: Drug: CKD-508 Tablet
Drug: Placebo Tablet

First Posted Date: 2024-12-10

Last Posted Date: 2024-12-17

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT06727396

Locations: 🇺🇸
Research Site, Glendale, California, United States

Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: CKD-378 25/1000mg

First Posted Date: 2024-11-29

Last Posted Date: 2025-05-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 31

Registration Number: NCT06709807

Locations: 🇰🇷
H Plus Yangji Hospital, Gwanak-gu, Seoul, Korea, Republic of

Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: CKD-383

First Posted Date: 2024-11-19

Last Posted Date: 2025-05-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT06695572

Locations: 🇰🇷
Bumin Hospital, Gangseo-gu, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy